Supplemental material
Open access
7,631
Views
60
CrossRef citations to date
0
Altmetric
Reports
Secukinumab, a novel anti–IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity
Anette KarleNovartis Pharma AG, Basel, Switzerland
, Sebastian SpindeldreherNovartis Pharma AG, Basel, Switzerland
& Frank KolbingerNovartis Pharma AG, Basel, SwitzerlandCorrespondence[email protected]
Pages 536-550
|
Received 10 Jul 2015, Accepted 22 Dec 2015, Published online: 04 Mar 2016
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.